DCIR2 Inhibitors
DCIR2 (Dendritic Cell Immunoreceptor 2), a member of the C-type lectin family, plays a pivotal role in immune regulation by modulating dendritic cell function and antigen presentation. The chemical class known as DCIR2 Inhibitors encompasses compounds targeting specific signaling pathways implicated in DCIR2-mediated immune responses. DCIR2 function is intricately linked to tyrosine kinase signaling pathways, particularly those involving Bcr-Abl, EGFR, VEGFR, and other receptor tyrosine kinases. Imatinib, a Bcr-Abl inhibitor, disrupts the Bcr-Abl signaling pathway, indirectly affecting DCIR2 by inhibiting downstream events associated with Bcr-Abl. Similarly, Dasatinib, Nilotinib, and Bosutinib target Bcr-Abl and other tyrosine kinases, influencing DCIR2-mediated immune regulation.
Other inhibitors, such as Sunitinib, Erlotinib, and Vandetanib, target receptor tyrosine kinases (VEGFR, EGFR) involved in angiogenic and cellular signaling pathways. Their indirect impact on DCIR2 involves modulating angiogenic signaling events, potentially affecting DCIR2 function in the regulation of immune responses and cellular processes. Crizotinib, Lapatinib, and Pazopanib, targeting ALK, MET, ROS1, HER2, and additional kinases, contribute to the inhibition of signaling pathways implicated in immune regulation. Sorafenib and Gefitinib, affecting RAF and EGFR pathways, respectively, further extend the repertoire of DCIR2 inhibitors. In summary, the chemical class of DCIR2 Inhibitors comprises a diverse array of compounds targeting specific tyrosine kinase signaling pathways associated with DCIR2-mediated immune regulation. Understanding the intricate interplay between these inhibitors and DCIR2 provides insights into potential strategies for modulating dendritic cell function, antigen presentation, and immune responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits the Bcr-Abl tyrosine kinase, disrupting the Bcr-Abl signaling pathway. Its indirect modulation of DCIR2 involves inhibiting the downstream signaling events associated with the Bcr-Abl pathway, potentially affecting DCIR2 function in immune regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits multiple tyrosine kinases, including Bcr-Abl. Its indirect influence on DCIR2 involves suppressing the activity of Bcr-Abl and associated signaling pathways, potentially impacting DCIR2-mediated immune responses. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib inhibits receptor tyrosine kinases, including VEGFR and PDGFR. Its indirect impact on DCIR2 involves modulating angiogenic signaling pathways, potentially affecting DCIR2 function in the context of immune responses and vascular regulation. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib inhibits Bcr-Abl tyrosine kinase, disrupting downstream signaling pathways. Its indirect modulation of DCIR2 involves inhibiting Bcr-Abl signaling, potentially influencing DCIR2-mediated immune regulation and cellular responses. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the EGFR tyrosine kinase, disrupting EGFR-mediated signaling. Its indirect influence on DCIR2 involves suppressing EGFR-related signaling pathways, potentially impacting DCIR2 function in the regulation of immune responses. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits EGFR and HER2 tyrosine kinases, disrupting their signaling pathways. Its indirect impact on DCIR2 involves modulating HER2-mediated signaling events, potentially affecting DCIR2 function in immune regulation and cellular responses. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases. Its indirect influence on DCIR2 involves modulating VEGFR, EGFR, or RET-related signaling pathways, potentially affecting DCIR2 function in immune responses and cellular regulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases, including VEGFR and RAF. Its indirect modulation of DCIR2 involves affecting VEGFR and RAF-related pathways, potentially influencing DCIR2-mediated immune responses and cellular regulation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits the EGFR tyrosine kinase, disrupting EGFR-mediated signaling. Its indirect influence on DCIR2 involves suppressing EGFR-related signaling pathways, potentially impacting DCIR2 function in the regulation of immune responses. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib inhibits VEGFR, PDGFR, and c-Kit tyrosine kinases. Its indirect impact on DCIR2 involves modulating VEGFR, PDGFR, or c-Kit-related signaling pathways, potentially affecting DCIR2 function in immune responses and cellular regulation. | ||||||